Slave, i also feel the wording in the reply is encouraging and a kind of indirect confirmation of good news. The application is definetely not dead as many suspect. Your further explaining about the letter brings more optimism for me. Game will be over to skeptics if we get approval for new and recurrent gbm indications plus or minus tissue agnostic label. I saw 15-20 cents when i was taking a position in this ticker years ago. There was nothing good at that time except a good hunch about this drug for me. The doctors and survivors statements about this treatment and the decent trial sites gave me the encouragement to start accumulating. Now after these many positive things, its silly to think of walking out. I cannot dispute the unusual delay . I will suffer through the pain for outcome. Its my decision and completely mine. Skeptics can concentrate on other investors to help. Thanks to lykiri for sharing it. Now the skeptics can go crazy for the rest of the evening.
Question to Slave1: Yesterday Blackmountain wrote (post 780732) that he/she sent a query to MHRA a few weeks ago and just received their answer in which it was stated that they they cannot comment on the status of applications during the review process,
Can that response still be considered to be compatible with the conclusion that we are already in the "labeling" stage because it can be interpreted to suggest that NWBO responded to an RFI and is now back on the clock but not yet in the labeling stage.
Market Data 
Markets 
AI
